Bridgeway Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bridgeway Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$280K	Sell	22,200 -7,500	-25%	-$101K	0.01%	950
2025 Q4	$468K	Hold	29,700	–	–	0.01%	834
2025 Q3	$356K	Hold	29,700	–	–	0.01%	882
2025 Q2	$225K	Buy	29,700 +10,000	+51%	+$60.2K	0.01%	936
2025 Q1	$109K	Sell	19,700 -26,500	-57%	-$164K	﹤0.01%	1024
2024 Q4	$266K	Sell	46,200 -1,800	-4%	-$17.3K	0.01%	950
2024 Q3	$497K	Buy	+48,000	New	+$628K	0.01%	862
2018 Q4	–	Sell	-26,600	Closed	-$2.27M	–	1396
2018 Q3	$2.27M	Buy	26,600 +2,800	+12%	+$280K	0.02%	578
2018 Q2	$2.76M	Buy	23,800 +600	+3%	+$59.9K	0.03%	507
2018 Q1	$1.88M	Sell	23,200 -250	-1%	-$19.2K	0.02%	615
2017 Q4	$1.38M	Buy	+23,450	New	+$1.17M	0.01%	711
2017 Q3	–	Sell	-20,000	Closed	-$720K	–	1414
2017 Q2	$720K	Hold	20,000	–	–	0.01%	960
2017 Q1	$616K	Hold	20,000	–	–	0.01%	991
2016 Q4	$670K	Hold	20,000	–	–	0.01%	960
2016 Q3	$532K	Hold	20,000	–	–	0.01%	1072
2016 Q2	$441K	Hold	20,000	–	–	0.01%	1096
2016 Q1	$587K	Hold	20,000	–	–	0.01%	976
2015 Q4	$660K	Buy	+20,000	New	+$652K	0.01%	946

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bridgeway Capital Management's ENTA Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Enanta Pharmaceuticals (ENTA) stake by 25% in Q1 2026, selling an estimated $101K and leaving 22,200 shares worth $280K. The position accounts for 0.01% of the portfolio, ranked #950.

Bridgeway Capital Management first reported a position in ENTA in Q4 2015 and has held it in 18 quarters since. The position peaked at $2.76M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Bridgeway Capital Management held 22,200 shares of Enanta Pharmaceuticals worth $280K as of Q1 2026.
Bridgeway Capital Management sold 7,500 Enanta Pharmaceuticals shares in Q1 2026, an estimated $101K.
Enanta Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #950 holding.
Bridgeway Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2015 and has held it in 18 quarters since.
Bridgeway Capital Management's Enanta Pharmaceuticals position peaked at $2.76M in Q2 2018.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.